X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13014) 13014
Publication (1124) 1124
Book Chapter (192) 192
Book Review (126) 126
Newsletter (87) 87
Conference Proceeding (39) 39
Newspaper Article (36) 36
Dissertation (32) 32
Magazine Article (23) 23
Reference (18) 18
Book / eBook (5) 5
Streaming Video (2) 2
Web Resource (2) 2
Data Set (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7097) 7097
animals (5417) 5417
male (4691) 4691
index medicus (4148) 4148
female (3386) 3386
aldosterone (3111) 3111
rats (2746) 2746
mineralocorticoid receptor (2658) 2658
mineralocorticoid receptor antagonists - therapeutic use (2126) 2126
endocrinology & metabolism (2080) 2080
hypertension (1794) 1794
spironolactone (1677) 1677
mineralocorticoid receptor antagonists (1581) 1581
middle aged (1522) 1522
adult (1493) 1493
receptors, mineralocorticoid - metabolism (1455) 1455
spironolactone - therapeutic use (1213) 1213
mineralocorticoids (1196) 1196
corticosteroids (1181) 1181
mineralocorticoid receptor antagonists - pharmacology (1105) 1105
aged (1100) 1100
spironolactone - pharmacology (1092) 1092
neurosciences (1089) 1089
steroids (1070) 1070
cardiac & cardiovascular systems (1048) 1048
peripheral vascular disease (1044) 1044
mice (977) 977
heart failure (960) 960
heart failure - drug therapy (929) 929
aldosterone - metabolism (903) 903
aldosterone - pharmacology (871) 871
spironolactone - analogs & derivatives (871) 871
receptors, mineralocorticoid - genetics (867) 867
blood-pressure (849) 849
biochemistry & molecular biology (847) 847
glucocorticoid receptor (846) 846
pharmacology & pharmacy (837) 837
receptors, glucocorticoid - metabolism (835) 835
physiology (807) 807
corticosterone (778) 778
eplerenone (773) 773
rats, sprague-dawley (744) 744
expression (735) 735
angiotensin-converting enzyme inhibitors - therapeutic use (724) 724
stress (719) 719
brain (708) 708
blood pressure - drug effects (705) 705
aldosterone - blood (704) 704
treatment outcome (698) 698
glucocorticoids (691) 691
hypertension - drug therapy (675) 675
blood pressure (673) 673
hypertension - physiopathology (657) 657
adrenalectomy (656) 656
cortisol (653) 653
mineralocorticoid receptors (636) 636
angiotensin-ii (626) 626
urology & nephrology (624) 624
time factors (614) 614
research (611) 611
rats, wistar (601) 601
heart-failure (596) 596
apparent mineralocorticoid excess (565) 565
oxidative stress (564) 564
mineralocorticoids - metabolism (559) 559
mortality (552) 552
hippocampus (545) 545
mineralocorticoid (541) 541
risk factors (523) 523
receptors, mineralocorticoid - physiology (522) 522
analysis (521) 521
medicine, general & internal (517) 517
aldosterone - physiology (515) 515
gene-expression (512) 512
physiological aspects (498) 498
sodium - metabolism (497) 497
dose-response relationship, drug (482) 482
kidney - metabolism (482) 482
cell biology (475) 475
hypertension - etiology (471) 471
article (470) 470
renin - blood (470) 470
receptors, glucocorticoid - genetics (464) 464
mineralocorticoid receptor antagonists - administration & dosage (462) 462
mineralocorticoid receptor antagonists - adverse effects (461) 461
adolescent (456) 456
cells, cultured (447) 447
drug therapy, combination (447) 447
rat (447) 447
fibrosis (439) 439
rna, messenger - metabolism (439) 439
11-beta-hydroxysteroid dehydrogenase (435) 435
disease models, animal (430) 430
gene expression (429) 429
heart failure - physiopathology (426) 426
kidney (416) 416
abridged index medicus (411) 411
myocardial-infarction (411) 411
receptors, mineralocorticoid (411) 411
adrenergic beta-antagonists - therapeutic use (404) 404
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11915) 11915
German (354) 354
French (340) 340
Japanese (268) 268
Russian (194) 194
Italian (116) 116
Spanish (108) 108
Polish (34) 34
Czech (26) 26
Danish (26) 26
Hungarian (23) 23
Chinese (22) 22
Portuguese (22) 22
Dutch (18) 18
Korean (12) 12
Bulgarian (8) 8
Swedish (5) 5
Ukrainian (5) 5
Norwegian (4) 4
Turkish (3) 3
Croatian (2) 2
Finnish (2) 2
Lithuanian (2) 2
Bosnian (1) 1
Icelandic (1) 1
Romanian (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Trends in Endocrinology & Metabolism, ISSN 1043-2760, 2015, Volume 26, Issue 4, pp. 201 - 211
Highlights • Mineralocorticoid receptor (MR) antagonists have proven benefits in hypertension and heart failure. • Atrial fibrillation (AF), pulmonary... 
Endocrinology & Metabolism | novel indications | mineralocorticoid receptor | spironolactone | eplerenone | Eplerenone | Spironolactone | Mineralocorticoid receptor | Novel indications | CHRONIC HEART-FAILURE | ALDOSTERONE ANTAGONISTS | MYOCARDIAL-INFARCTION | PLASMA-ALDOSTERONE | LEFT-VENTRICULAR HYPERTROPHY | ANTI-ALDOSTERONE | ATRIAL-FIBRILLATION | RENIN-ANGIOTENSIN SYSTEM | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | STAGE RENAL-DISEASE | Severity of Illness Index | Arrhythmias, Cardiac - prevention & control | Receptors, Mineralocorticoid - agonists | Cardiovascular Diseases - physiopathology | Off-Label Use | Cardiovascular Diseases - metabolism | Receptors, Mineralocorticoid - metabolism | Cardiovascular Diseases - drug therapy | Humans | Death, Sudden, Cardiac - prevention & control | Arrhythmias, Cardiac - etiology | Death, Sudden, Cardiac - etiology | Disease Progression | Hypertension, Pulmonary - prevention & control | Mineralocorticoid Receptor Antagonists - therapeutic use | Heart Failure - prevention & control | Cardiovascular Agents - therapeutic use | Animals | Models, Biological | Heart Failure - etiology | Hypertension, Pulmonary - etiology | Receptors, Mineralocorticoid - chemistry | Heart failure | Hypertension | Heart | Hospitals | Atrial fibrillation | Steroids | Cardiovascular Diseases | Receptors, Mineralocorticoid | Hypertension, Pulmonary | Arrhythmias, Cardiac | Cardiovascular Agents | Death, Sudden, Cardiac | Life Sciences | Human health and pathology | Heart Failure | Mineralocorticoid Receptor Antagonists | Cardiology and cardiovascular system
Journal Article
Hypertension, ISSN 0194-911X, 04/2018, Volume 71, Issue 4, pp. 609 - 621
Stiffening of the vasculature with aging is a strong predictor of adverse cardiovascular events, independent of all other risk factors including blood... 
Receptors | Gene expression profiling | Mineralocorticoid | Smooth muscle | Blood pressure | Myocytes | Vascular stiffening | blood pressure | receptors | HEART-FAILURE | smooth muscle | ANGIOTENSIN-II | AORTIC STIFFNESS | myocytes | mineralocorticoid | vascular stiffening | ARTERIAL STIFFNESS | DISEASE | VASCULAR INFLAMMATION | PERIPHERAL VASCULAR DISEASE | ALDOSTERONE | CARDIAC FIBROSIS | gene expression profiling | MOLECULAR-MECHANISMS | GENE-TRANSCRIPTION | Receptors, Mineralocorticoid - genetics | Gene Expression - drug effects | Muscle, Smooth, Vascular - metabolism | Receptors, Mineralocorticoid - metabolism | Humans | Cellular Senescence - drug effects | Male | Gene Expression Profiling | Spironolactone - metabolism | Fibrosis - metabolism | Mineralocorticoid Receptor Antagonists - metabolism | Spironolactone - pharmacology | Mineralocorticoid Receptor Antagonists - pharmacology | Fibrosis - prevention & control | Myocytes, Smooth Muscle - drug effects | Myocytes, Smooth Muscle - metabolism | Muscle, Smooth, Vascular - drug effects | Cellular Senescence - physiology | Treatment Outcome | Disease Progression | Muscle, Smooth, Vascular - pathology | Animals | Exercise Tolerance - physiology | Vascular Stiffness - drug effects | Vascular Stiffness - physiology | Aged | Mice | Fibrosis - pathology | Hormone receptors | Care and treatment | Fibrosis | Aging | Physiological aspects | Mineralocorticoids | Development and progression | Health aspects | Heart diseases | mineralocorticoid receptors | smooth muscle cell | aging | vascular fibrosis
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 04/2016, Volume 133, Issue 14, pp. 1360 - 1370
BACKGROUND—The hypertensive syndrome of Apparent Mineralocorticoid Excess is caused by loss-of-function mutations in the gene encoding 11β-hydroxysteroid... 
pressoreceptors | salt | solitary nucleus | mineralocorticoids | aldosterone | APPARENT MINERALOCORTICOID EXCESS | CARDIAC & CARDIOVASCULAR SYSTEMS | SODIUM APPETITE | BAROREFLEX SENSITIVITY | DISTAL TUBULE | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-2 | HEART-FAILURE | INTRACEREBROVENTRICULAR INFUSION | BLOOD-PRESSURE | PERIPHERAL VASCULAR DISEASE | MICE | Mineralocorticoid Excess Syndrome, Apparent - drug therapy | Mineralocorticoid Excess Syndrome, Apparent - genetics | Nerve Tissue Proteins - deficiency | Solitary Nucleus - enzymology | Receptors, Mineralocorticoid - physiology | RNA, Messenger - biosynthesis | Nephrons - physiopathology | Dexamethasone - pharmacology | Spironolactone - pharmacology | Reflex, Abnormal | Nestin - genetics | Neurons - physiology | Mineralocorticoid Excess Syndrome, Apparent - physiopathology | Craving - physiology | Corticosterone - blood | Hypertension - genetics | 11-beta-Hydroxysteroid Dehydrogenase Type 2 - genetics | Solitary Nucleus - physiopathology | Nerve Tissue Proteins - physiology | Mice, Inbred C57BL | Genes, Synthetic | Nerve Tissue Proteins - genetics | Hypertension - physiopathology | Drinking Behavior | Mice, Knockout | Mineralocorticoid Receptor Antagonists - therapeutic use | Baroreflex - drug effects | Animals | Sodium Chloride, Dietary - toxicity | Potassium - urine | 11-beta-Hydroxysteroid Dehydrogenase Type 2 - metabolism | 11-beta-Hydroxysteroid Dehydrogenase Type 2 - physiology | Mice | Hypertension | Measurement | Care and treatment | Phenylephrine | Blood pressure | Dosage and administration | Cardiovascular diseases | 10111 | 10014 | 10058 | Original
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 02/2014, Volume 34, Issue 2, pp. 355 - 364
OBJECTIVE—Vascular remodeling occurs after endothelial injury, resulting in smooth muscle cell (SMC) proliferation and vascular fibrosis. We previously... 
placental growth factor | receptors mineralocorticoid | vascular endothelial growth factor receptor-1 | aldosterone | myocytes smooth muscle | MORTALITY | OXIDATIVE STRESS | EVENTS | receptors | smooth muscle | myocytes | mineralocorticoid | BLOOD-PRESSURE | SPIRONOLACTONE | PERIPHERAL VASCULAR DISEASE | EPLERENONE | HYPERTENSION | HEMATOLOGY | EXPRESSION | BLOCKER | GENE-TRANSCRIPTION | Carotid Arteries - drug effects | Carotid Arteries - metabolism | Receptors, Mineralocorticoid - agonists | Receptors, Mineralocorticoid - genetics | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Muscle, Smooth, Vascular - metabolism | Pregnancy Proteins - genetics | Myocytes, Smooth Muscle - pathology | Male | Pregnancy Proteins - metabolism | RNA, Messenger - metabolism | Receptors, Mineralocorticoid - deficiency | Time Factors | Carotid Artery Injuries - genetics | Myocytes, Smooth Muscle - drug effects | Myocytes, Smooth Muscle - metabolism | Carotid Artery Injuries - metabolism | Carotid Artery Injuries - pathology | Disease Models, Animal | Muscle, Smooth, Vascular - drug effects | Endothelial Cells - metabolism | Mice, Inbred C57BL | Aldosterone - pharmacology | Vascular Endothelial Growth Factor Receptor-1 - metabolism | Mice, Knockout | Antibodies - pharmacology | Muscle, Smooth, Vascular - pathology | Animals | Fibrosis | Placenta Growth Factor | Carotid Arteries - pathology | Cell Proliferation - drug effects | Mice | Endothelial Cells - pathology | Endothelial Cells - drug effects | smooth muscle cells | mineralocorticoid receptor | vascular remodeling | VEGF
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 08/2015, Volume 761, pp. 226 - 234
The present study was designed to characterize the pharmacological profile of CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist. In the... 
CS-3150 | Aldosterone | Urinary Na+/K+ ratio | Mineralocorticoid receptor antagonist | Urinary Na | ratio | TARGET | OXIDATIVE STRESS | DIABETIC-NEPHROPATHY | MESSENGER-RNA | PHARMACOKINETICS | SPIRONOLACTONE | INFLAMMATION | ALDOSTERONE BLOCKER | PHARMACOLOGY & PHARMACY | HYPERTENSION | EPLERENONE | Receptors, Mineralocorticoid - genetics | Urological Agents - pharmacology | Antihypertensive Agents - pharmacology | Pyrroles - pharmacokinetics | Receptors, Mineralocorticoid - metabolism | Humans | Transcriptional Activation - drug effects | Rats, Inbred WKY | Desoxycorticosterone Acetate | Male | Water-Electrolyte Balance - drug effects | Spironolactone - metabolism | Sulfones - pharmacology | Dose-Response Relationship, Drug | Receptors, Mineralocorticoid - drug effects | Aldosterone - metabolism | Spironolactone - pharmacology | Transfection | Sodium - urine | Pyrroles - administration & dosage | Hypertension - chemically induced | HEK293 Cells | Mineralocorticoid Receptor Antagonists - pharmacology | Hypertension - prevention & control | Female | Blood Pressure - drug effects | Radioligand Assay | Spironolactone - analogs & derivatives | Disease Models, Animal | Binding, Competitive | Mineralocorticoid Receptor Antagonists - administration & dosage | Rabbits | Administration, Oral | Aldosterone - pharmacology | Sulfones - pharmacokinetics | Rats, Sprague-Dawley | Hypertension - physiopathology | Adrenalectomy | Pyrroles - pharmacology | Animals | Eplerenone | Potassium - urine | Protein Binding | Mineralocorticoid Receptor Antagonists - pharmacokinetics | Sulfones - administration & dosage | Hypertension | Hormones, Sex | Corticosteroids | Drug discovery | Spironolactone
Journal Article
Journal Article
Journal of Psychopharmacology, ISSN 0269-8811, 12/2013, Volume 27, Issue 12, pp. 1169 - 1179
Background: Treatment-resistant depression patients show both reduced glucocorticoid receptor function and a hyperactive hypothalamic-pituitary-adrenal axis.... 
hypothalamic-pituitary-adrenal axis | prednisolone | Cortisol | mineralocorticoid receptor | treatment resistant depression | mineralocorticoid receptor antagonist | PSYCHIATRY | PREDNISOLONE SUPPRESSION TEST | HUMANS | CHILDHOOD EXPERIENCE | MAJOR DEPRESSION | NEUROSCIENCES | CLINICAL NEUROLOGY | CANRENOATE | GLUCOCORTICOID-RECEPTOR | PHARMACOLOGY & PHARMACY | HPA AXIS | PITUITARY-ADRENAL AXIS | BRAIN | Single-Blind Method | Mineralocorticoid Receptor Antagonists - administration & dosage | Prednisolone - administration & dosage | Spironolactone - administration & dosage | Pituitary-Adrenal System - metabolism | Receptors, Mineralocorticoid - metabolism | Humans | Middle Aged | Hydrocortisone - metabolism | Male | Receptors, Glucocorticoid - metabolism | Saliva - chemistry | Prednisolone - pharmacology | Case-Control Studies | Hypothalamo-Hypophyseal System - metabolism | Spironolactone - pharmacokinetics | Depressive Disorder, Treatment-Resistant - physiopathology | Receptors, Mineralocorticoid - drug effects | Spironolactone - pharmacology | Canrenone - metabolism | Mineralocorticoid Receptor Antagonists - pharmacology | Female | Receptors, Glucocorticoid - drug effects | Mineralocorticoid Receptor Antagonists - pharmacokinetics | Physiological aspects | Mineralocorticoids | Hypothalamic-pituitary-adrenal axis | Care and treatment | Research | Depression, Mental
Journal Article
The FASEB Journal, ISSN 0892-6638, 08/2014, Volume 28, Issue 8, pp. 3745 - 3757
The mineralocorticoid receptor (MR) controls adipocyte function, but its role in the conversion of white adipose tissue (WAT) into thermogenic fat has not been... 
metabolic syndrome | uncoupling protein 1 | UCP1 | adipogenesis | aldosterone | obesity | Obesity | Aldosterone | Metabolic syndrome | Uncoupling protein 1 | Adipogenesis | BIOCHEMISTRY & MOLECULAR BIOLOGY | MOUSE | ADULT HUMANS | ORGAN | CELL BIOLOGY | GLUCOSE-HOMEOSTASIS | IN-VIVO | BIOLOGY | GENE-EXPRESSION | DIFFERENTIATION | Inguinal Canal | Obesity - drug therapy | Adipogenesis - drug effects | Diet, High-Fat - adverse effects | Ion Channels - genetics | Adipocytes - cytology | Androstenes - pharmacology | Gene Expression Profiling | Mitochondrial Proteins - genetics | Adipocytes - drug effects | Autophagy - drug effects | Adipogenesis - physiology | Receptors, Mineralocorticoid - physiology | Receptors, Mineralocorticoid - drug effects | Glucose Intolerance - prevention & control | Spironolactone - pharmacology | Body Composition - drug effects | Glucose Intolerance - etiology | Cell Transdifferentiation - drug effects | Mineralocorticoid Receptor Antagonists - pharmacology | Macrolides - pharmacology | Female | Weight Gain - drug effects | Intra-Abdominal Fat - drug effects | Spironolactone - therapeutic use | Ion Channels - biosynthesis | Mice, Inbred C57BL | Cells, Cultured | Androstenes - therapeutic use | Aldosterone - pharmacology | Obesity - physiopathology | Mitochondrial Proteins - biosynthesis | Mineralocorticoid Receptor Antagonists - therapeutic use | Up-Regulation - drug effects | Animals | Obesity - prevention & control | Adipose Tissue, Brown - metabolism | Mice | Uncoupling Protein 1 | Adipose Tissue, White - drug effects
Journal Article
Journal of Neuroendocrinology, ISSN 0953-8194, 08/2016, Volume 28, Issue 8, pp. np - n/a
Journal Article